China NT Pharma : Announcement of Approval of Xi Di Ke (Uroacitides Injection), National Class 1.1 New Drug to…

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01011) ANNOUNCEMENT OF APPROVAL OF XI DI KE, NATIONAL CLASS 1.1 NEW DRUG (UROACITIDES INJECTION) TO ENTER THE MARKET

This announcement is made by China NT Pharma Group Company Limited (the "Company") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board of directors (the "Board") of the Company is pleased to announce that, Xi Di Ke (uroacitides injection), a national Class 1.1 new drug developed by Jiangsu NT Biopharma Co., Ltd. ("NT Biopharma"), a subsidiary of the Company, has obtained approval from China Food and Drug Administration ("CFDA") to enter the market (Number of drug approval: Guo Yao Zhun Zi H20163446).

Xi Di Ke®(the brand name of uroacitides injection) is a national Class 1.1 new drug with global exclusive intellectual property rights and relevant patent, which has obtained approval from CFDA to be launched in the market for the treatment of non-small cell lung cancer and breast cancer. Its newly added indication is "Myelodysplastic Syndrome (MDS)", which is a hematological malignancy, of which approximately one-third of patients will develop leukemia. Approval for conducting Phase II clinical research for the treatment of the new indication, MDS, using Xi Di Ke has been granted by CFDA. Such research is being conducted in 15 clinical research centres (hospitals) across China, and it has been admitted into the shortlist of "Major New Drugs Innovation and Development" projects of the Ministry of Science and Technology. NT Biopharma will be responsible for the production and launching and sales of Xi Di Ke.

The approval of launching of Xi Di Ke®represents a significant breakthrough in the innovation of new drugs of the Company and its subsidiaries (the "Group"). The uniqueness and exclusivity of the product will expand the product mix of the Group in relation to the treatment of tumours and bring strong support to its business.

By order of the Board

China NT Pharma Group Company Limited Ng Tit

Chairman

Hong Kong, the PRC, 4 January 2017

As at the date of this announcement, the executive Directors of the Company are Mr. Ng Tit, Ms. Chin Yu and Mr. Wu Weizhong; the non-executive Directors of the Company are Dr. Qian Wei and Mr. Ge Jianqiu; and the independent non-executive Directors of the Company are Mr. Yue Nien Martin Tang, Mr. Patrick Sun and Dr. Lap-Chee Tsui.